---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-003043"
form_type: "8-K"
ticker: "SMTI"
cik: "0000714256"
company_name: "Sanara MedTech Inc."
filed_at: "2025-01-21T23:59:59+00:00"
generated_at: "2026-05-27T22:38:26.438693+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sanara MedTech reports Q4 prelim net revenue up 45-48% YoY; FY up 32-33%

## Summary
- Q4 2024 net revenue expected $25.7M-$26.2M, a 45-48% increase YoY.
- Full year 2024 net revenue expected $86.0M-$86.5M, up 32-33% YoY.
- BIASURGE sales benefited from ~$1.8M in temporary demand due to hurricane-related IV fluid shortages; expects normalization in Q1 2025.
- Cash at Dec 31, 2024: $15.9M; debt $30.5M; $24.5M available borrowing capacity.
- Appointed Keith Myers (former LHC Group CEO) to Board on Oct 4, 2024; filed 11 provisional patent applications in 2024.

## SEC filing metadata
- accession: 0001493152-25-003043
- form_type: 8-K
- ticker: SMTI
- cik: 0000714256
- company_name: Sanara MedTech Inc.
- filed_at: 2025-01-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/714256/000149315225003043/0001493152-25-003043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/714256/000149315225003043/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-003043
- JSON: https://secwatch.observer/filing/0001493152-25-003043.json
- Plain text: https://secwatch.observer/filing/0001493152-25-003043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.